Deal with Idorsia gives Santhera shot at second DMD candidate

In a deal that will make Idorsia Ltd. (SIX:IDIA) its largest shareholder, Santhera Pharmaceuticals Holding AG (SIX:SANN) gained an option to exclusively in-license a second Duchenne muscular dystrophy candidate: vamorolone (VBP15).

Santhera CEO Thomas Meier told BioCentury vamorolone -- in testing for younger, still-ambulant DMD patients to preserve limb muscle function -- would complement Santhera's development of Raxone idebenone for preserving respiratory function in typically non-ambulant patients...